Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica

Kathy Holliman  |  Issue: April 2012  |  April 6, 2012

The new classification criteria of SS require that a patient have at least two of the following objective features:

  • Positive serum anti-SSA and/or anti-SSB or positive rheumatoid factor plus antinuclear antibodies ≥1:320;
  • Ocular staining score ≥3; and
  • Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus score ≥1 foci/4 mm2.

Implications for Clinical Practice

Although the classification criteria for SS are straightforward and objective, using these criteria may be challenging, Dr. Criswell says. One of the challenges will be the need for earlier collaboration and interaction with other specialists, including ophthalmologists and oral medicine specialists, for classification. These specialists are also necessary for the ongoing management of SS patients. “While a rheumatologist might have felt comfortable doing a Schirmer’s test to measure dry eyes, a rheumatologist typically would not be using a slit lamp, which is required for ocular staining and assessment.” The need for this extra assessment “could be seen as a disadvantage, but we feel it is a tremendous service to the patient, given that ocular manifestations can have devastating complications,” she says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Also, an oral medicine specialist will need to perform the labial salivary gland biopsy. Without that biopsy and assessment, an opportunity will be missed to document and quantify the autoinflammatory component of the disease and to begin treating the patient for the progressive effects of hyposalivation, Dr. Criswell says. A subset of patients with SS is at greater risk for developing lymphoma than patients with other autoimmune diseases. The biopsy can identify early lymphoma or a patient at high risk for the disease.

Some patients with SS do not complain of dry eyes or dry mouth, even though both symptoms have been considered hallmarks of the disease. Ocular staining or a biopsy of the salivary gland tissue can provide clear evidence of SS. “A syndrome of dry eyes and dry mouth can have many causes,” Dr. Criswell says. “We want these new criteria to identify those individuals who have an autoimmune basis for those symptoms. This arms clinicians and researchers with a new tool to identify and target individuals who have dry eye and dry mouth as part of an autoimmune disease.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

These criteria formally say that if you have rheumatoid serology, you are much less likely to have PMR. None of the other criteria out there for polymyalgia, diagnostic or otherwise, have addressed that. That is very important.

—Eric L. Matteson, MD

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsSjögren’s Disease Tagged with:AC&RAmerican College of Rheumatology (ACR)Classification CriteriaGuidelinesOsteoarthritisPolymyalgia RheumaticarheumatologistSjogren's

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    January 29, 2024

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    How to Manage Polymyalgia Rheumatica

    December 16, 2015

    Recognizing the need to provide guidance on the current disparate management of polymyalgia rheumatica (PMR), the American College of Rheumatology (ACR), in collaboration with the European League Against Rheumatism (EULAR), recently published the first international set of recommendations for the screening, treatment and management of PMR.1,2 Specifically, the recommendations offer guidance on the use of…

    Permanent Vision Loss in Late Giant Cell Arteritis

    October 18, 2018

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences